What were FDA officials doing behind closed doors with those trial lawyers, anyway?. This question has been nagging generic drug makers for several weeks as they scramble to fend off .  they worry will leave them more vulnerable to costly lawsuits.. The rule would let generic drug makers independently add new side effect information to product labeling, something that only brand-name drugs makers are currently allowed to do before receiving FDA permission. The proposal was made last fall in response to .  that generic drug makers are not required to make such changes and, therefore, should not be held accountable for a failure to warn against any risks.. More on this after the jump…